Benjamin Rs Dixon1, Alison Nankervis1,2, Stephanie Cn Hopkins1, Thomas J Cade1,3. 1. Department of Maternity Services & Pregnancy Research Centre, The Royal Women's Hospital, Parkville, Australia. 2. Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Australia. 3. Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Australia.
Abstract
BACKGROUND: Insulin delivery options for pregnant women with type 1 diabetes mellitus are either continuous subcutaneous insulin infusion or multiple daily injections. The aim of this paper is to compare pregnancy outcomes in women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion or multiple daily injections in pregnancy. METHODS: Retrospective single-centre cohort study of 298 pregnancies booked between 2006 and 2016. Descriptive analysis was performed for HbA1c values. Logistic regression models were created to compare selected maternal and neonatal outcomes. RESULTS: Continuous subcutaneous insulin infusion was associated with increased risk of large-for-gestational age (aOR 2.00, 95% CI 1.20-3.34) and preterm neonates (aOR 1.80, 95% CI 1.04-3.03). Continuous subcutaneous insulin infusion had no association with increased risk of adverse pregnancy outcomes. No difference in HbA1c values existed between groups. CONCLUSION: Using continuous subcutaneous insulin infusion for type 1 diabetes mellitus through pregnancy is associated with increased risk of large-for-gestational age and preterm neonates, without increased risk of associated adverse maternal or neonatal outcomes.
BACKGROUND: Insulin delivery options for pregnant women with type 1 diabetes mellitus are either continuous subcutaneous insulin infusion or multiple daily injections. The aim of this paper is to compare pregnancy outcomes in women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion or multiple daily injections in pregnancy. METHODS: Retrospective single-centre cohort study of 298 pregnancies booked between 2006 and 2016. Descriptive analysis was performed for HbA1c values. Logistic regression models were created to compare selected maternal and neonatal outcomes. RESULTS: Continuous subcutaneous insulin infusion was associated with increased risk of large-for-gestational age (aOR 2.00, 95% CI 1.20-3.34) and preterm neonates (aOR 1.80, 95% CI 1.04-3.03). Continuous subcutaneous insulin infusion had no association with increased risk of adverse pregnancy outcomes. No difference in HbA1c values existed between groups. CONCLUSION: Using continuous subcutaneous insulin infusion for type 1 diabetes mellitus through pregnancy is associated with increased risk of large-for-gestational age and preterm neonates, without increased risk of associated adverse maternal or neonatal outcomes.
Authors: Kristel J M Janssen; A Rogier T Donders; Frank E Harrell; Yvonne Vergouwe; Qingxia Chen; Diederick E Grobbee; Karel G M Moons Journal: J Clin Epidemiol Date: 2010-03-24 Impact factor: 6.437
Authors: Katarzyna Cyganek; Alicja Hebda-Szydlo; Barbara Katra; Jan Skupien; Tomasz Klupa; Izabela Janas; Irena Kaim; Jacek Sieradzki; Alfred Reron; Maciej T Malecki Journal: Diabetes Technol Ther Date: 2010-01 Impact factor: 6.118
Authors: Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter Journal: BMJ Date: 2009-06-29
Authors: N Wah Cheung; Jennifer J Conn; Michael C d'Emden; Jenny E Gunton; Alicia J Jenkins; Glynis P Ross; Ashim K Sinha; Sofianos Andrikopoulos; Stephen Colagiuri; Stephen M Twigg Journal: Med J Aust Date: 2009-09-21 Impact factor: 7.738